loading
前日終値:
$10.35
開ける:
$10.38
24時間の取引高:
31.23M
Relative Volume:
1.53
時価総額:
$3.63B
収益:
$64.60M
当期純損益:
$-377.75M
株価収益率:
-5.9871
EPS:
-1.55
ネットキャッシュフロー:
$-335.64M
1週間 パフォーマンス:
-11.87%
1か月 パフォーマンス:
+34.88%
6か月 パフォーマンス:
+21.78%
1年 パフォーマンス:
-24.98%
1日の値動き範囲:
Value
$9.15
$10.60
1週間の範囲:
Value
$9.15
$12.36
52週間の値動き範囲:
Value
$5.60
$15.74

Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile

Name
名前
Recursion Pharmaceuticals Inc
Name
セクター
Healthcare (1169)
Name
電話
(385) 269-0203
Name
住所
41S RIO GRANDE STREET, SALT LAKE CITY
Name
職員
500
Name
Twitter
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
RXRX's Discussions on Twitter

RXRX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RXRX
Recursion Pharmaceuticals Inc
9.28 3.63B 64.60M -377.75M -335.64M -1.55
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.24 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
700.33 76.56B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
644.48 39.16B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
250.59 32.44B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
120.01 28.77B 3.30B -501.07M 1.03B -2.1146

Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-05-22 開始されました Morgan Stanley Equal-Weight
2023-03-16 開始されました Needham Buy
2022-09-16 開始されました KeyBanc Capital Markets Overweight
2022-04-18 ダウングレード BofA Securities Buy → Neutral
2022-03-04 ダウングレード SVB Leerink Outperform → Mkt Perform
2021-09-21 開始されました Berenberg Buy
2021-05-11 開始されました BofA Securities Buy
2021-05-11 開始されました Goldman Neutral
2021-05-11 開始されました JP Morgan Neutral
2021-05-11 開始されました KeyBanc Capital Markets Overweight
2021-05-11 開始されました SVB Leerink Outperform
すべてを表示

Recursion Pharmaceuticals Inc (RXRX) 最新ニュース

pulisher
05:30 AM

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL

05:30 AM
pulisher
04:17 AM

Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite? - MSN

04:17 AM
pulisher
Feb 21, 2025

Top Biotech Stocks To ConsiderFebruary 20th - MarketBeat

Feb 21, 2025
pulisher
Feb 21, 2025

Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite? - MarketBeat

Feb 21, 2025
pulisher
Feb 21, 2025

Cathie Wood Explains Why She Likes Recursion Pharmaceuticals, Inc. (RXRX) - MSN

Feb 21, 2025
pulisher
Feb 20, 2025

Biotech Stocks Worth WatchingFebruary 15th - MarketBeat

Feb 20, 2025
pulisher
Feb 19, 2025

Why Recursion Pharmaceuticals, Inc. (RXRX) is the Best Performing Healthcare Stock So Far in 2025 - MSN

Feb 19, 2025
pulisher
Feb 19, 2025

Recursion Pharma Accelerator Steps In to Fill Some of the Funding Gap Amid NIH Tumult - MedCity News

Feb 19, 2025
pulisher
Feb 19, 2025

Backed by Recursion CEO, Altitude Lab venture aims to fill gap from NIH cuts - MM+M Online

Feb 19, 2025
pulisher
Feb 19, 2025

10 Best Performing Healthcare Stocks So Far in 2025 - Insider Monkey

Feb 19, 2025
pulisher
Feb 19, 2025

Recursion CEO launches pre-seed fund in response to NIH cuts - BioPharma Dive

Feb 19, 2025
pulisher
Feb 19, 2025

Why Jensen Huang’s Company Is Betting On Recursion Pharmaceuticals, Inc. (RXRX) - MSN

Feb 19, 2025
pulisher
Feb 19, 2025

Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City - The Manila Times

Feb 19, 2025
pulisher
Feb 19, 2025

Can This New Biotech Fund Save 1,500 Startups Hit by SBIR Changes? - StockTitan

Feb 19, 2025
pulisher
Feb 19, 2025

Could this Nvidia-backed growth stock be a millionaire-maker at $10? - Yahoo Finance UK

Feb 19, 2025
pulisher
Feb 19, 2025

Recursion CEO: Publicly funded research built the biopharma industry. Now it needs our help - STAT

Feb 19, 2025
pulisher
Feb 18, 2025

Why Recursion Pharmaceuticals, Inc. (RXRX) Soared on Wednesday - MSN

Feb 18, 2025
pulisher
Feb 18, 2025

Recursion Pharmaceuticals Stock Scores RS Ratings Over 90 - MSN

Feb 18, 2025
pulisher
Feb 18, 2025

5 Stocks Jensen Huang’s Company is Betting On - Insider Monkey

Feb 18, 2025
pulisher
Feb 18, 2025

Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock - MSN

Feb 18, 2025
pulisher
Feb 18, 2025

Altitude Lab's Startup Portfolio Hits $154M Milestone: Inside the Biotech Incubator's Success Story - StockTitan

Feb 18, 2025
pulisher
Feb 18, 2025

25 Top AI Stocks That Could Boost Your Portfolio - The Motley Fool

Feb 18, 2025
pulisher
Feb 18, 2025

SoftBank Joins Nvidia In Backing Recursion Pharma, Retail Traders Rally Behind Stock Surge - NewsBreak

Feb 18, 2025
pulisher
Feb 17, 2025

Nvidia-Backed Recursion Pharma Hits 3-Week High, Sparks Retail Buzz Amid Broader AI Hype - MSN

Feb 17, 2025
pulisher
Feb 17, 2025

Best Biotech Stocks To Keep An Eye OnFebruary 14th - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Promising Mid Cap Stocks To Add to Your WatchlistFebruary 16th - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

The Rise of Recursion Pharmaceuticals: A Biotech Stock on the Move - RagingBull

Feb 17, 2025
pulisher
Feb 17, 2025

Promising Biotech Stocks To Follow NowFebruary 17th - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Why Recursion Pharmaceuticals, Inc. (RXRX) Soared Last Week - MSN

Feb 17, 2025
pulisher
Feb 16, 2025

SoftBank reports new stakes in PacBio, Recursion Pharmaceuticals - MSN

Feb 16, 2025
pulisher
Feb 15, 2025

Recursion Pharmaceuticals (NASDAQ: RXRX) Surges Nearly 24% as Nvidia Retains Stake – market - HPBL

Feb 15, 2025
pulisher
Feb 15, 2025

Recursion Pharmaceuticals Stock Soars as Nvidia Maintains Stake – A Vote of Confidence? – market - HPBL

Feb 15, 2025
pulisher
Feb 15, 2025

Recursion Pharmaceuticals (RXRX) Sees Institutional Investors Adjust Positions Amid Market Volatility - HPBL

Feb 15, 2025
pulisher
Feb 15, 2025

Institutional Investors Bet Big on Recursion Pharmaceuticals (RXRX) Amid Growing Biotech Interest - HPBL

Feb 15, 2025
pulisher
Feb 15, 2025

Why Recursion Pharmaceuticals (RXRX) Skyrocketed 23.88% on Friday – market - HPBL

Feb 15, 2025
pulisher
Feb 15, 2025

Recursion Pharmaceuticals (RXRX): A Biotech Stock Outpacing the Market with Explosive Growth - HPBL

Feb 15, 2025
pulisher
Feb 15, 2025

Recursion Pharmaceuticals (RXRX) Stock Surges 15%: Nvidia’s Vote of Confidence Sparks AI Biotech Rally - HPBL

Feb 15, 2025
pulisher
Feb 15, 2025

Recursion Pharmaceuticals Stock Surges 15.8% as Nvidia Retains Stake – market - HPBL

Feb 15, 2025
pulisher
Feb 15, 2025

Mirae Asset Global Investments Co. Ltd. Sells 74,818 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

Shares of 10 Firms Soar on Friday - Insider Monkey

Feb 15, 2025
pulisher
Feb 15, 2025

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 8.6%What's Next? - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

Why Recursion Pharmaceuticals Inc. (RXRX) Soared on Friday? - MSN

Feb 15, 2025
pulisher
Feb 14, 2025

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 8.6% HigherWhat's Next? - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

Best Mid Cap Stocks To Follow TodayFebruary 14th - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

Why Recursion Pharmaceuticals Stock Is Soaring Today - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

Best Pharmaceutical Stocks To Watch NowFebruary 14th - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

Cathie Wood Doubles Down on 3D Systems, Blade Air Mobility, and Recursion Pharmaceuticals: Key Moves for Ark Invest – market - HPBL

Feb 14, 2025
pulisher
Feb 14, 2025

SoftBank Latest Moves: Major Stakes in PacBio, Recursion Pharmaceuticals and Better Home & Finance - HPBL

Feb 14, 2025
pulisher
Feb 14, 2025

Recursion Pharmaceuticals (RXRX) Stock Soars 15.8%, Nvidia Confidence Boosts Investor Sentiment - HPBL

Feb 14, 2025
pulisher
Feb 14, 2025

Recursion Pharmaceuticals Soars 15.8% Amid Nvidia Confidence Boost – market - HPBL

Feb 14, 2025

Recursion Pharmaceuticals Inc (RXRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Recursion Pharmaceuticals Inc (RXRX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Gibson Christopher
Chief Executive Officer
Feb 05 '25
Sale
7.68
20,000
153,600
1,273,156
$33.42
price up icon 0.27%
$81.06
price down icon 3.05%
$361.10
price down icon 1.70%
$22.12
price down icon 4.08%
biotechnology ONC
$255.37
price up icon 4.57%
$120.01
price up icon 1.81%
大文字化:     |  ボリューム (24 時間):